Pathophysiology of arrhythmogenic cardiomyopathy

Nature Reviews Cardiology

Volumn 9, Issue 4, 2012, Pages 223-233

  Basso, Cristina ^a   Bauce, Barbara ^a   Corrado, Domenico ^a   Thiene, Gaetano ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DESMOCOLLIN; DESMOCOLLIN 2; DESMOGLEIN 2; DESMOPLAKIN; ION CHANNEL; PLAKOGLOBIN; PLAKOPHILIN; PLAKOPHILIN 2; SOTALOL; UNCLASSIFIED DRUG;

ARRHYTHMOGENIC CARDIOMYOPATHY; CARDIOMYOPATHY; CATHETER ABLATION; CELL NUCLEUS; DESMOSOME; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE COURSE; DYSTROPHY; EXERCISE; GAP JUNCTION; GENE MUTATION; GENETIC SCREENING; HEART ATRIUM FIBRILLATION; HEART MUSCLE NECROSIS; HUMAN; LUNG EMBOLISM; MEDICAL LITERATURE; MYOCARDIAL DYSTROPHY; MYOCARDITIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; RELATIVE; REVIEW; SENSITIVITY AND SPECIFICITY;

ANIMALS; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; DEATH, SUDDEN, CARDIAC; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEART FUNCTION TESTS; HUMANS; PREDICTIVE VALUE OF TESTS; TERMINOLOGY AS TOPIC; VENTRICULAR FUNCTION, RIGHT;

EID: 84859111164     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2011.173     Document Type: Review

References (98)

1. Online Medical Inheritance in Man®. 107970 Arrhythmogenic right ventricular dysplasia, familial, 1; ARVD1 [online], http://omim.org/entry/107970 (2009).
2. Basso, C., Corrado, D., Marcus, F. I., Nava, A. & Thiene, G. Arrhythmogenic right ventricular cardiomyopathy. Lancet 373, 1289-1300 (2009).
3. Thiene, G., Nava, A., Corrado, D., Rossi, L. & Pennelli, N. Right ventricular cardiomyopathy and sudden death in young people. N. Engl. J. Med. 318, 129-133 (1988). (Pubitemid 18035134)
4. Corrado, D., Thiene, G., Nava, A., Pennelli, N. & Rossi, L. Sudden death in young competitive athletes: clinico-pathologic correlations in 22 cases. Am. J. Med. 89, 588-596 (1990). (Pubitemid 20384315)
5. Awad, M. M., Calkins, H. & Judge D. P. Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nat. Clin. Pract. Cardiovasc. Med. 5, 258-267 (2008). (Pubitemid 351593909)
6. Basso, C. et al. Arrhythmogenic right ventricular cardiomyopathy: dysplasia, dystrophy or myocarditis? Circulation 94, 983-991 (1996). (Pubitemid 26292851)
7. Basso, C., Corrado, D. & Thiene, G. Arrhythmogenic right ventricular cardiomyopathy: what's in a name? From a congenital defect (dysplasia) to a genetically determined cardiomyopathy (dystrophy). Am. J. Cardiol. 106, 275-277 (2010).
8. Frank, R. et al. Electrocardiology of 4 cases of right ventricular dysplasia inducing arrhythmia. Arch. Mal. Coeur Vaiss. 71, 963-972 (1978). (Pubitemid 9026766)
9. Marcus, F. et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation 65, 384-398 (1982). (Pubitemid 12219036)
10. Uhl, H. S. A previously undescribed congenital malformation of the heart: almost total absence of the myocardium of the right ventricle. Bull. Johns Hopkins Hosp. 91, 197-209 (1952).
11. McKenna, W. J. et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br. Heart J. 71, 215-218 (1994). (Pubitemid 24113523)
12. Richardson, P. et al. Report of the World Health Organization/ International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 93, 841-842 (1996). (Pubitemid 26074816)
13. Gallo P, d'Amati, G. & Pelliccia, F. Pathologic evidence of extensive left ventricular involvement in arrhythmogenic right ventricular cardiomyopathy. Hum. Pathol. 23, 948-952 (1992).
14. Michalodimitrakis, M., Papadomanolakis, A., Stiakakis, J. & Kanaki, K. Left side right ventricular cardiomyopathy. Med. Sci. Law 42, 313-317 (2002).
15. Nava, A., Rossi, L. & Thiene, G. (Eds) Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (Elsevier, Amsterdam, 1997).
16. Marcus, F., Nava, A. & Thiene, G. (Eds) Arrhythmogenic RV Cardiomyopathy/Dysplasia: Recent Advances (Springer-Verlag, Milan, 2007).
17. Corrado, D., Basso, C., Thiene, G. Arrhythmogenic Cardiomyopathy, An Issue of Cardiac Electrophysiology Clinics (Elsevier, New York, 2011).
18. Corrado, D., Basso, C., Pilichou, K. & Thiene, G. Molecular biology and clinical management of arrhythmogenic right ventricular cardiomyopathy/ dysplasia. Heart 97, 530-539 (2011).
19. Marcus, F. I. et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur. Heart J. 31, 806-814 (2010).
20. Asimaki, A. et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N. Engl. J. Med. 360, 1075-1084 (2009).
21. Asimaki, A. et al. Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy. Circ. Arrhythm. Electrophysiol. 4, 743-752 (2011).
22. Tandri, H. et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J. Am. Coll. Cardiol. 45, 98-103 (2005). (Pubitemid 40052034)
23. Sen Chowdhry, S. et al. Cardiovascular magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited: comparison with task force criteria and genotype. J. Am. Coll. Cardiol. 48, 2132-2140 (2006).
24. Sen Chowdhry, S. et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J. Am. Coll. Cardiol. 52, 2175-2187 (2008).
25. Sen Chowdhry, S. et al. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 115, 1710-1720 (2007).
26. Corrado, D. et al. Three-dimensional electroanatomic voltage mapping increases accuracy of diagnosing arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 111, 3042-3050 (2005). (Pubitemid 40847780)
27. Corrado, D. et al. Three-dimensional electroanatomical voltage mapping and histologic evaluation of myocardial substrate in right ventricular outflow tract tachycardia. J. Am. Coll. Cardiol. 51, 731-739 (2008). (Pubitemid 351221209)
28. Garcia, F. C., Bazan, V., Zado, E. S., Ren, J. F. & Marchlinski, F. E. Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 120, 366-375 (2009).
29. Bauce, B. et al. Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations. Eur. Heart J. 26, 1666-1675 (2005). (Pubitemid 41389699)
30. Corrado, D. et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J. Am. Coll. Cardiol. 30, 1512-1520 (1997). (Pubitemid 27486470)
31. Nava, A. et al. Familial occurrence of right ventricular dysplasia: a study involving nine families. J. Am. Coll. Cardiol. 12, 1222-1228 (1988).
32. McKoy, G. et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 355, 2119-2124 (2000). (Pubitemid 30364661)
33. Rampazzo, A. et al. The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23 q24. Hum. Mol. Genet. 3, 959-962 (1994). (Pubitemid 24189967)
34. Norgett, E. E. et al. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum. Mol. Genet. 9, 2761-2766 (2000).
35. Protonotarios, N. & Tsatsopoulou, A. Naxos disease and Carvajal syndrome: cardiocutaneous disorders that highlight the pathogenesis and broaden the spectrum of arrhythmogenic right ventricular cardiomyopathy. Cardiovasc. Pathol. 13, 185-194 (2004). (Pubitemid 38798357)
36. Kaplan, S. R. et al. Structural and molecular pathology of the heart in Carvajal syndrome. Cardiovasc. Pathol. 13, 26-32 (2004). (Pubitemid 38169463)
37. Rampazzo, A. et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am. J. Hum. Genet. 71, 1200-1206 (2002). (Pubitemid 35305239)
38. Nava, A. et al. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J. Am. Coll. Cardiol. 36, 2226-2233 (2000).
39. Gerull, B. et al. Mutations in the desmosomal protein plakophilin 2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat. Genet. 36, 1162-1164 (2004). (Pubitemid 41288964)
40. Pilichou, K. et al. Mutations in desmoglein 2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation 113, 1171-1179 (2006).
41. Syrris, P. et al. Arrhythmogenic right ventricular dysplasia/ cardiomyopathy associated with mutations in the desmosomal gene desmocollin 2. Am. J. Hum. Genet. 79, 978-984 (2006). (Pubitemid 44763413)
42. Asimaki, A. et al. A novel dominant mutation in plakoglobin causes arrhythmogenic right ventricular cardiomyopathy. Am. J. Hum. Genet. 81, 964-973 (2007). (Pubitemid 47580249)
43. Awad, M. M. et al. Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in PKP2. Hum. Mutat. 27, 1157 (2006).
44. Simpson, M. A. et al. Homozygous mutation of desmocollin 2 in arrhythmogenic right ventricular cardiomyopathy with mild palmoplantar keratoderma and woolly hair. Cardiology 113, 28-34 (2009).
45. Tiso, N. et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum. Mol. Genet. 10, 189-194 (2001). (Pubitemid 32123976)
46. Beffagna, G. et al. Regulatory mutations in transforming growth factor β3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc. Res. 65, 366-373 (2005). (Pubitemid 40082478)
47. Merner, N. D. et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am. J. Hum. Genet. 82, 1-13 (2008).
48. van Tintelen, J. P. et al. Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene. Heart Rhythm 6, 1574-1583 (2009).
49. Taylor, M. et al. Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy-overlap syndromes. Circulation 124, 876-885 (2011).
50. Protonotarios, N. et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia on the basis of the revised diagnostic criteria in affected families with desmosomal mutations. Eur. Heart J. 32, 1097-1104 (2011).
51. Quarta, G. et al. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation 123, 1201-1209 (2011).
52. den Haan, A. D. et al. Comprehensive desmosome mutation analysis in North Americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ. Cardiovasc. Genet. 2, 428-435 (2009).
53. Cox, M. G. et al. Arrhythmogenic right ventricular dysplasia/ cardiomyopathy: pathogenic desmosome mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dysplasia/cardiomyopathy genotype-phenotype follow-up study. Circulation 123, 2690-2700 (2011).
54. Bauce, B. et al. Multiple mutations in desmosomal proteins encoding genes in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm 7, 22-29 (2010).
55. Xu, T. et al. Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J. Am. Coll. Cardiol. 55, 587-589 (2010).
56. Kapplinger, J. D. et al. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. J. Am. Coll. Cardiol. 57, 2317-2327 (2011).
57. Charron, P. et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 31, 2715-2726 (2010).
58. Delmar, M. & McKenna, W. J. The cardiac desmosome and arrhythmogenic cardiomyopathies: from gene to disease. Circ. Res. 107, 700-714 (2010).
59. Franke, W. W., Borrmann, C. M., Grund, C. & Pieperhoff, S. The area composita of adhering junctions connecting heart muscle cells of vertebrates. I. Molecular definition in intercalated disks of cardiomyocytes by immunoelectron microscopy of desmosomal proteins. Eur. J. Cell. Biol. 85, 69-82 (2006). (Pubitemid 43137112)
60. Mallat, Z. et al. Evidence of apoptosis in arrhythmogenic right ventricular dysplasia. N. Engl. J. Med. 335, 1190-1196 (1996). (Pubitemid 26339773)
61. Valente, M. et al. In vivo evidence of apoptosis in arrhythmogenic right ventricular cardiomyopathy. Am. J. Pathol. 152, 479-484 (1998). (Pubitemid 28106394)
62. Pilichou, K. et al. Myocyte necrosis underlies progressive myocardial dystrophy in mouse dsg2-related arrhythmogenic right ventricular cardiomyopathy. J. Exp. Med. 206, 1787-1802 (2009).
63. Li, J. et al. Cardiac tissue-restricted deletion of plakoglobin results in progressive cardiomyopathy and activation of β catenin signaling. Mol. Cell. Biol. 31, 1134-1144 (2011).
64. Yang, Z. et al. Desmosomal dysfunction due to mutations in desmoplakin causes arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ. Res. 99, 646-655 (2006). (Pubitemid 44401456)
65. Basso, C. et al. Ultrastructural evidence of intercalated disc remodelling in arrhythmogenic right ventricular cardiomyopathy: an electron microscopy investigation on endomyocardial biopsies. Eur. Heart J. 27, 1847-1854 (2006). (Pubitemid 44297392)
66. Garcia Gras, E. et al. Suppression of canonical Wnt/β catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J. Clin. Invest. 116, 2012-2021 (2006).
67. Li, D. et al. Restrictive loss of plakoglobin in cardiomyocytes leads to arrhythmogenic cardiomyopathy. Hum. Mol. Genet. 20, 4582-4596 (2011).
68. Krusche, C. A. et al. Desmoglein 2 mutant mice develop cardiac fibrosis and dilation. Basic Res. Cardiol. 106, 617-633 (2011).
69. Kaplan, S. R. et al. Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease). Heart Rhythm 1, 3-11 (2004). (Pubitemid 38647241)
70. Sato, P. Y. et al. Loss of plakophilin 2 expression leads to decreased sodium current and slower conduction velocity in cultured cardiac myocytes. Circ. Res. 105, 523-526 (2009).
71. Sato, P. Y. et al. Interactions between ankyrin G., plakophilin 2, and connexin 43 at the cardiac intercalated disc. Circ. Res. 109, 193-201 (2011).
72. Thiene, G. et al. Right ventricular cardiomyopathy: is there evidence of an inflammatory aetiology? Eur. Heart J. 12, 22-25 (1991).
73. Calabrese, F., Basso, C., Carturan, E., Valente, M. & Thiene, G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: is there a role for viruses? Cardiovasc. Pathol. 15, 11-17 (2006). (Pubitemid 43088765)
74. Bowles, N. E., Ni, J., Marcus, F. & Towbin, J. A. The detection of cardiotropic viruses in the myocardium of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J. Am. Coll. Cardiol. 39, 892-895 (2002). (Pubitemid 34185340)
75. Bonny, A. et al. C reactive protein in arrhythmogenic right ventricular dysplasia/cardiomyopathy and relationship with ventricular tachycardia. Cardiol. Res. Pract. 2010, 919783 (2010).
76. Campian, M. E. et al. Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur. J. Nucl. Med. Mol. Imaging 37, 2079-2085 (2010).
77. d'Amati, G., di Gioia, C. R., Giordano, C. & Gallo, P. Myocyte transdifferentiation: a possible pathogenetic mechanism for arrhythmogenic right ventricular cardiomyopathy. Arch. Pathol. Lab. Med. 124, 287-290 (2000). (Pubitemid 30090617)
78. Lombardi, R. et al. Genetic fate mapping identifies second heart field progenitor cells as a source of adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ. Res. 104, 1076-1084 (2009).
79. Gittenberger-de Groot, A. C., Winter, E. M. & Poelmann, R. E. Epicardium-derived cells (EPDCs) in development, cardiac disease and repair of ischemia. J. Cell. Mol. Med. 14, 1056-1060 (2010).
80. Liang, W. C. et al. TMEM43 mutations in Emery-Dreifuss muscular dystrophy-related myopathy. Ann. Neurol. 69, 1005-1013 (2011).
81. Sen Chowdhry, S. et al. Mutational heterogeneity, modifier genes, and environmental influences contribute to phenotypic diversity of arrhythmogenic cardiomyopathy. Circ. Cardiovasc. Genet. 3, 323-330 (2010).
82. Bauce, B. et al. Comparison of clinical features of arrhythmogenic right ventricular cardiomyopathy in men versus women. Am. J. Cardiol. 102, 1252-1257 (2008).
83. Pelzer, T. et al. 17β Estradiol prevents programmed cell death in cardiac myocytes. Biochem. Biophys. Res. Commun. 268, 192-200 (2000). (Pubitemid 30116632)
84. Wlodarska, E. K. et al. Arrhythmogenic right ventricular cardiomyopathy in two pairs of monozygotic twins. Int. J. Cardiol. 105, 126-133 (2005). (Pubitemid 41512477)
85. Gonzalez Juanatey, C., Testa, A. & Armesto, V. Identical twins with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Clin. Cardiol. 30, 529-530 (2007). (Pubitemid 47587508)
86. Pilichou, K., Bezzina, C. R., Thiene, G. & Basso, C. Arrhythmogenic cardiomyopathy: transgenic animal models provide novel insights into disease pathobiology. Circ. Cardiovasc. Genet. 4, 318-326 (2011).
87. Kirchhof, P. et al. Age-and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation 114, 1799-1806 (2006). (Pubitemid 44673354)
88. Corrado, D., Basso, C., Rizzoli, G., Schiavon, M. & Thiene, G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J. Am. Coll. Cardiol. 42, 1959-1963 (2003). (Pubitemid 37485572)
89. Fabritz, L. et al. Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. J. Am. Coll. Cardiol. 57, 740-750 (2011).
90. Corrado, D. et al. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA 296, 1593-1601 (2006). (Pubitemid 44515020)
91. Pelliccia, A. et al. Outcomes in athletes with marked ECG repolarization abnormalities. N. Engl. J. Med. 358, 152-161 (2008).
92. Wichter, T., Borggrefe, M., Haverkamp, W., Chen, X. & Breithardt, G. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 86, 29-37 (1992).
93. Wichter, T. et al. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD? Herz 30, 91-101 (2005). (Pubitemid 40576527)
94. Marchlinski, F. E. et al. Electroanatomic substrate and outcome of catheter ablative therapy for ventricular tachycardia in setting of right ventricular cardiomyopathy. Circulation 110, 2293-2298 (2004). (Pubitemid 39407329)
95. Dalal, D. et al. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J. Am. Coll. Cardiol. 50, 432-440 (2007). (Pubitemid 47088123)
96. Corrado, D. et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 108, 3084-3091 (2003). (Pubitemid 38031796)
97. Corrado, D. et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation 122, 1144-1152 (2010).
98. Bushby, K., Lochmüller, H., Lynn, S. & Straub, V. Interventions for muscular dystrophy: molecular medicines entering the clinic. Lancet 374, 1849-1856 (2009).